{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:19:50Z","timestamp":1790277590364,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T00:00:00Z","timestamp":1377129600000},"content-version":"vor","delay-in-days":1604,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1016\/j.seizure.2008.09.004","type":"journal-article","created":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T09:02:04Z","timestamp":1225530124000},"page":"184-192","source":"Crossref","is-referenced-by-count":25,"title":["Add-on treatment with pregabalin for partial seizures with or without generalisation: Pooled data analysis of four randomised placebo-controlled trials"],"prefix":"10.1016","volume":"18","author":[{"given":"Antonio","family":"Gil-Nagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Zaccara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Baldinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2008.09.004_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/syn.10094","article-title":"Preferential action of gabapentin and pregabalin at P\/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices","volume":"45","author":"Dooley","year":"2002","journal-title":"Synapse"},{"issue":"Suppl. 6","key":"10.1016\/j.seizure.2008.09.004_bib2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.0013-9580.2004.455003.x","article-title":"Pregabalin pharmacology and its relevance to clinical practice","volume":"45","author":"Ben-Menachem","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2008.09.004_bib3","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1124\/mol.106.023309","article-title":"Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons","volume":"70","author":"Micheva","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.seizure.2008.09.004_bib4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.eplepsyres.2006.09.008","article-title":"Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery","volume":"73","author":"Taylor","year":"2007","journal-title":"Epilepsy Res"},{"issue":"Suppl. 8","key":"10.1016\/j.seizure.2008.09.004_bib5","first-page":"35","article-title":"Profile of the anticonvulsant activity of CI-1008 (pregabalin) in animal models","volume":"38","author":"Taylor","year":"1997","journal-title":"Epilepsia"},{"issue":"Suppl. 2","key":"10.1016\/j.seizure.2008.09.004_bib6","first-page":"A36","article-title":"Meta-analysis of add-on treatment in drug resistant partial epilepsy: a comprehensive study of 41 randomized controlled trials among 10 AEDs","volume":"66","author":"Ryvlin","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2008.09.004_bib7","doi-asserted-by":"crossref","first-page":"17537","DOI":"10.1073\/pnas.0409066103","article-title":"Identification of the \u03b12-\u03b4-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin","volume":"103","author":"Field","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.seizure.2008.09.004_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.0013-9580.2004.455004.x","article-title":"Pregabalin as adjunctive therapy for partial seizures","volume":"45","author":"Brodie","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2008.09.004_bib9","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1111\/j.1528-1167.2005.19204.x","article-title":"Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy","volume":"46","author":"Brodie","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2008.09.004_bib10","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1212\/01.WNL.0000068024.20285.65","article-title":"Dose\u2013response trial of pregabalin adjunctive therapy in patients with partial seizures","volume":"60","author":"French","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2008.09.004_bib11","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.0013-9580.2004.31203.x","article-title":"Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose\u2013response study in adults with partial seizures","volume":"45","author":"Arroyo","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2008.09.004_bib12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1212\/01.WNL.0000150932.48688.BE","article-title":"Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy","volume":"64","author":"Beydoun","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2008.09.004_bib13","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/j.1528-1167.2005.00341.x","article-title":"Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study","volume":"46","author":"Elger","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2008.09.004_bib14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures: from the Commission on Classification and Terminology of the International League Against Epilepsy","volume":"22","year":"1981","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2008.09.004_bib15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0920-1211(01)00216-9","article-title":"Proof of efficacy trials: endpoints","volume":"45","author":"French","year":"2001","journal-title":"Epilepsy Res"},{"issue":"Suppl. 4","key":"10.1016\/j.seizure.2008.09.004_bib16","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1468-1331.2005.01327.x","article-title":"Defining success in clinical trials\u2014profiling pregabalin, the newest AED","volume":"12","author":"Ryvlin","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.seizure.2008.09.004_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S1059-1311(03)00047-5","article-title":"Measuring the efficacy of antiepileptic drugs","volume":"12","author":"Mohanraj","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2008.09.004_bib18","series-title":"Coding symbols for a thesaurus of adverse events reaction terms (COSTART)","author":"Department of Health and Human Services","year":"1996"},{"key":"10.1016\/j.seizure.2008.09.004_bib19","series-title":"Poster presented at the 7th European Congress on Epileptology","article-title":"Modeling of weight change associated with placebo and pregabalin administration","author":"Miller","year":"2006"},{"key":"10.1016\/j.seizure.2008.09.004_bib20","series-title":"Poster presented at the 7th European Congress on Epileptology","article-title":"Predictive performance of weight change associated with pregabalin administration","author":"Barrett","year":"2006"},{"key":"10.1016\/j.seizure.2008.09.004_bib21","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/01.wnf.0000159956.87511.67","article-title":"Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy","volume":"28","author":"Otoul","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.seizure.2008.09.004_bib22","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1528-1157.1997.tb01251.x","article-title":"The new antiepileptic drugs: a systematic review of their efficacy and tolerability","volume":"38","author":"Marson","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2008.09.004_bib23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0920-1211(01)00287-X","article-title":"Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review","volume":"46","author":"Marson","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2008.09.004_bib24","first-page":"CD001909","article-title":"Lamotrigine add-on for drug-resistant partial epilepsy","volume":"3","author":"Ramaratnam","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.seizure.2008.09.004_bib25","first-page":"CD001901","article-title":"Levetiracetam add-on for drug-resistant localization related (partial) epilepsy","volume":"1","author":"Chaisewikul","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.seizure.2008.09.004_bib26","first-page":"CD002028","article-title":"Oxcarbazepine add-on for drug-resistant partial epilepsy","volume":"3","author":"Castillo","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.seizure.2008.09.004_bib27","first-page":"CD001415","article-title":"Gabapentin add-on for drug-resistant partial epilepsy","volume":"3","author":"Marson","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.seizure.2008.09.004_bib28","first-page":"CD001908","article-title":"Tiagabine add-on for drug-resistant partial epilepsy","volume":"3","author":"Pereira","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.seizure.2008.09.004_bib29","first-page":"CD001417","article-title":"Topiramate add-on for drug-resistant partial epilepsy","volume":"3","author":"Jette","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.seizure.2008.09.004_bib30","first-page":"CD001416","article-title":"Zonisamide add-on for drug-resistant partial epilepsy","author":"Chadwick","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"Suppl. 5","key":"10.1016\/j.seizure.2008.09.004_bib31","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1111\/j.1528-1157.1999.tb00919.x","article-title":"Evidence-based medicine and antiepileptic drugs","volume":"40","author":"Privitera","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2008.09.004_bib32","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1684\/j.1950-6945.2006.tb00170.x","article-title":"Measurement of seizure freedom in adjunctive therapy studies in refractory partial epilepsy: the levetiracetam experience","volume":"8","author":"Leppik","year":"2006","journal-title":"Epileptic Disord"},{"issue":"Suppl. 4","key":"10.1016\/j.seizure.2008.09.004_bib33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1528-1157.2001.0420s4031.x","article-title":"Efficacy of levetiracetam: a review of three pivotal clinical trials","volume":"42","author":"Privitera","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2008.09.004_bib34","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1046\/j.1528-1157.2003.62802.x","article-title":"Seizure-free days observed in randomized placebo-controlled add-on trials with levetiracetam in partial epilepsy","volume":"44","author":"Leppik","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2008.09.004_bib35","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2008.09.004_bib36","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2008.09.004_bib37","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000mg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2008.09.004_bib38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1684\/j.1950-6945.2006.tb00157.x","article-title":"Identifying baseline characteristics of placebo responders versus nonresponders in randomized double-blind trials of refractory partial-onset seizures","volume":"8","author":"Niklson","year":"2006","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2008.09.004_bib39","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1517\/14656566.7.15.2139","article-title":"Pregabalin for the treatment of generalised anxiety disorder","volume":"7","author":"Montgomery","year":"2006","journal-title":"Exp Opin Pharmacother"},{"issue":"Suppl. 4","key":"10.1016\/j.seizure.2008.09.004_bib40","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.yebeh.2003.10.002","article-title":"Psychiatric comorbidity in patients with epilepsy: implications for diagnosis and treatment","volume":"4","author":"Devinsky","year":"2003","journal-title":"Epilepsy Behav"},{"issue":"Suppl. 4","key":"10.1016\/j.seizure.2008.09.004_bib41","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.yebeh.2003.10.005","article-title":"Epilepsy and anxiety","volume":"4","author":"Vazquez","year":"2003","journal-title":"Epilepsy Behav"}],"updated-by":[{"DOI":"10.1016\/j.seizure.2009.09.009","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000}}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131108002057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131108002057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T13:19:31Z","timestamp":1738502371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131108002057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["S1059131108002057"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2008.09.004","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}